Trump's pharmaceutical tariffs could affect some drugmakers more than others ○
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Steve Scala
since
auto-detected in 1 stories
6 months ago
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
page 1 of 1